Safety and Tolerability of BL-1020 in Hospitalized Subjects With Chronic Schizophrenia or Schizo-Affective Disorder

Exclusion Criteria

• •Pregnant or lactating women
• •administration of clozapine within 60 days prior to Baseline
• •DSM-IV diagnosis of schizophreniform disorder (295.40) or schizophrenia residual sub-type (295.60), or other primary psychiatric diagnoses, such as bipolar disorder or major depressive disorder
• •Severity of psychosis rated severe or higher (CGI-S 6 or 7)
• •Known suicidal risk (modified ISST score\>7)
• •Requiring disallowed concomitant psychotropic medication following enrolment into the study
• •Current evidence of clinically significant or unstable illness
• •Clinically significant abnormal laboratory data (e.g. creatinine, AST or ALT greater than 3 x the upper limit of normal, TSH\>10 IU) at screening, or any abnormal laboratory values that could interfere with the assessment of safety (e.g. blood cell count, etc.).